Compound research
CJC-1295: Research Overview & Current Status
CJC-1295 is a long-acting growth hormone-releasing hormone (GHRH) analog. Current research status: in clinical trials. CJC-1295 has been studied in small, sponsor-run Phase 1/2-type human pharmacokinetic and safety trials but has not been approved by the FDA for any indication and is not marketed as a prescription drug.
Overview
CJC-1295 is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH 1-29), modified with amino-acid substitutions and, in the drug affinity complex (DAC) form, a moiety that binds circulating albumin to extend its half-life to roughly 8 days. It was developed to sustain elevated growth hormone and IGF-1 levels for research purposes.
long-acting growth hormone-releasing hormone (GHRH) analog
Research timeline
2006
Teichman et al. published randomized, placebo-controlled, double-blind ascending-dose trials (28 and 49 days) of CJC-1295 in healthy adults ages 21-61, reporting dose-dependent GH and IGF-1 increases.
Source →2006
A companion study in the Journal of Clinical Endocrinology & Metabolism examined whether pulsatile GH secretion persists during continuous CJC-1295 stimulation.
Source →
Active & recent research
Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295 in Healthy Adults
pharmacokinetics, pharmacodynamics, and safety of subcutaneous CJC-1295 in healthy adults
Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295
characterizing GH pulsatility patterns and correlation with IGF-1 production after CJC-1295 administration
Key findings
- The 2006 Teichman study reported that a single CJC-1295 injection produced dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 or more days, and IGF-1 concentrations by 1.5- to 3-fold for 9-11 days.
- The same study concluded subcutaneous CJC-1295 was 'safe and relatively well tolerated' at doses of 30 or 60 mcg/kg in the trial population, with evidence of a cumulative effect after multiple doses.
- A companion study reported that CJC-1295 binds to endogenous albumin after injection, extending its half-life to approximately 8 days, and that pulsatile GH secretion persisted during continuous stimulation.
Safety & regulatory notes
CJC-1295 is not FDA-approved and has only been evaluated in small early-phase human trials conducted by its original commercial sponsor; no large-scale or long-term human safety data are publicly available. It is classified by the World Anti-Doping Agency (WADA) under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) as prohibited in and out of competition. It is sold only as a research chemical and has no standardized approved human dosing.
We may earn a commission when readers buy through links on this page, at no extra cost to you. Commissions never affect a vendor's score — every vendor is graded on the same public rubric built from published lab documentation, live catalog pricing, and community sentiment. How we score →
Where it's sold for research
We haven't built a dedicated vendor-availability page for CJC-1295 yet. See our full research-peptide vendor rankings →
CJC-1295 FAQ
Is CJC-1295 FDA-approved?+
No. CJC-1295 has been studied in small early-phase human trials but has not received FDA approval for any medical use.
What is CJC-1295 studied for?+
Published human research has examined its ability to sustain elevated growth hormone and IGF-1 levels via its GHRH-receptor-binding, long-half-life mechanism.
Is CJC-1295 legal to buy for research purposes?+
It is sold by some suppliers labeled for research/laboratory use only; it has no approved therapeutic indication and is prohibited for competitive athletes under WADA's S2 category.
Is CJC-1295 the same as growth hormone?+
No. CJC-1295 is a GHRH analog that stimulates the pituitary to release the body's own growth hormone, rather than being growth hormone itself.
Sources for this page (3)
Related: all compound research overviews · research radar · full vendor rankings · methodology